SOUTH SAN FRANCISCO, Calif. — BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BBO-11818 for the treatment of adult patients with advanced KRAS-mutant pancreatic ductal adenocarcinoma. “Receiving Fast...

Paris, France – AB Science SA (Euronext – FR0010557264 – AB) announced the publication of a new article on the preprint platform medRxiv, evaluating long-term amyotrophic lateral sclerosis (ALS) survivors treated with masitinib at 4.5 mg/kg/day in the phase 2b/3 AB10015 study. The article is titled ‘Evaluation of Long-Term Amyotrophic Lateral...

By Louise Rodino-Klapac – PhD President of Research & Development at Sarepta Therapeutics Cambridge, Mass. – Momentum in Duchenne muscular dystrophy was palpable at the Muscular Dystrophy Association Scientific Congress last month. With nearly 180 abstracts focused on Duchenne alone, spanning pre-clinical research to post-market experience, the field is at...